Tamiflu_75mg_german_closeup
Photo via Wikimedia Commons

As anyone whoโ€™s suffered through it can tell you, getting the flu โ€” the real influenza flu, not just some fly-by-night bug โ€” is miserable. If youโ€™ve got a compromised immune system, it can even be deadly. Thatโ€™s one reason individuals (and governments!) have invested in anti-flu medicines like Tamiflu and Relenza. But thereโ€™s just one catch: According to recent research by a University of Maryland doctor, these anti-flu treatments donโ€™t really work.Peter Doshi, assistant professor of pharmaceutical health services at UMDโ€™s School of Pharmacy co-authored this review of other studies, which found that anti-flu drugs might be more trouble than theyโ€™re worth. There was insufficient evidence to support Tamifluโ€™s claim that it reduces hospital admissions or limits severe symptoms. While Tamiflu proved to be effective at shortening the diseaseโ€™s duration by a half-day, it also increased patientsโ€™ risk of nausea and vomiting by a small amount. When the drug was taken for an extended period of time, patients were at greater risk of headaches, renal problems, and the ominous โ€œpsychiatric disturbances.โ€

โ€œIโ€™m not interested in health scares,โ€ Doshi says. โ€œWhat weโ€™ve found here are statistically significant increases. Do I know absolutely for certain, without a shadow of a doubt, that Tamiflu is responsible for these (negative effects), based on the trial methodology? No. But what Iโ€™m seeing here are clear reasons to be concerned and to look into it further.โ€

This isnโ€™t just a question of whether any particular individual chooses to take anti-flu medication; it also touches on national health care issues. The United States has spent over $1 billion on anti-virals like Tamifluโ€“ you know, in case some terrible strain of influenza happens to strike again. Despite Doshiโ€™s research, the Centers for Disease Control remain firm: โ€œWe carefully review all available data including randomized controlled trials and observational studies when making recommendations,โ€ they wrote in a release. โ€œThere is a substantial and growing number of observational studies that show the clinical benefit of antiviral treatment of seasonal and pandemic influenza.โ€